REGARD: what can we learn from randomised, open-label, head-to-head studies?
Sørensen
Per Soelberg
PS
D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D007155:Immunologic Factors